Fresh Tracks Therapeutics Fresh Tracks Therapeutics Home
  • Company
    • Vision
    • Values
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partner With Us
    • Join Us
  • Scientific Innovations
  • Pipeline
    • Overview
    • FRTX-02
    • FRTX-10
    • Next-Generation Kinase Inhibitors
    • FRTX-03
  • Investor Relations
Main Menu
Contact Us
Investor Relations

News

Investors

Investors

  • Overview
  • News
  • Events
  • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
Apr 29, 2021 8:00am EDT

Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021

Apr 27, 2021 7:30am EDT

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Apr 23, 2021 10:01am EDT

Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis

Apr 16, 2021 10:00am EDT

Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX

Apr 15, 2021 8:00am EDT

Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology

Mar 09, 2021 4:01pm EST

Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Mar 05, 2021 8:00am EST

Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market

Feb 25, 2021 4:05pm EST

Brickell Biotech to Participate in March Virtual Investor Conferences

Feb 23, 2021 4:01pm EST

Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021

Jan 19, 2021 7:00am EST

Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

  • Previous Pagearrow_back
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Pagearrow_forward
  • Email Alerts
  • RSS News Feed

Company

  • Vision
  • Values
  • Leadership
  • Partner With Us
  • Join Us

Discover

  • Scientific Innovations
  • Pipeline
  • Investor Relations
  • News
  • Contact Us

Follow Us

  • LinkedIn
  • Twitter
  • Instagram
  • Facebook
  • Compliance
  • Terms of Use
  • Privacy Policy
  • Accessibility
©2023 Fresh Tracks Therapeutics, Inc.

We use first- and third-party cookies to obtain statistical information to personalize our website and provide you with a better experience. If you continue without changing your settings, this demonstrates your consent to receive all cookies or other tracking technologies on the FRTX website for the purposes described in our Privacy Policy. Please know that you can change your cookie settings at any time in your browser settings.

Close